Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer

Overview

Journal Drugs

Specialty Pharmacology

Date 2019 Oct 21

PMID 31630379

Citations 30

Authors

Vassilis Aggelis

Stephen R D Johnston

Affiliations

Soon will be listed here.

Abstract

Approximately 70% of breast cancers are estrogen-receptor positive. Tamoxifen and aromatase inhibitors have been the mainstay of endocrine therapy and have improved breast cancer survival. However, a large number of patients experience disease recurrence either during or following completion of endocrine therapy. Recent improvements in our understanding of the various mechanisms underlying the development of endocrine resistance have led to a dramatic change in the landscape of current endocrine treatment with the introduction of new drugs targeting molecular pathways involved in endocrine resistance. Over the past years we have witnessed the use of combination endocrine therapy with mammalian target of rapamycin antagonists, whilst most recently the introduction of cyclin-dependent kinase 4/6 inhibitors has significantly improved response to endocrine therapy. Whilst not a formal systematic review, this article will provide historical background and summarise key clinical trials and current strategies in both first-line and second-line endocrine therapy.

Citing Articles

Targeting estrogen-regulated system x promotes ferroptosis and endocrine sensitivity of ER+ breast cancer.

Cao J, Zhou T, Wu T, Lin R, Huang J, Shi D Cell Death Dis. 2025; 16(1):30.

PMID: 39833180 PMC: 11756422. DOI: 10.1038/s41419-025-07354-0.

The present and future of the Cancer Dependency Map.

Arafeh R, Shibue T, Dempster J, Hahn W, Vazquez F Nat Rev Cancer. 2024; 25(1):59-73.

PMID: 39468210 DOI: 10.1038/s41568-024-00763-x.

Obesity-Senescence-Breast Cancer: Clinical Presentation of a Common Unfortunate Cycle.

Engin A, Engin A Adv Exp Med Biol. 2024; 1460:821-850.

PMID: 39287873 DOI: 10.1007/978-3-031-63657-8_27.

Effects of Curcumin and Estrogen Receptor Alpha in Luminal Breast Cancer Cells.

Palacios-Navarro L, Crispin L, Munoz J, Calaf G Diagnostics (Basel). 2024; 14(16).

PMID: 39202273 PMC: 11353822. DOI: 10.3390/diagnostics14161785.

A narrative review of the clinical development of CDK4/6 inhibitor abemaciclib in breast cancer.

Yang L, Chen Y, Wang N, Han W Transl Breast Cancer Res. 2024; 3:4.

PMID: 38751545 PMC: 11093002. DOI: 10.21037/tbcr-21-36.

References

Thangavel C, Dean J, Ertel A, Knudsen K, Aldaz C, Witkiewicz A . Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011; 18(3):333-45. PMC: 3624623. DOI: 10.1530/ERC-10-0262. View

Smith I, Dowsett M . Aromatase inhibitors in breast cancer. N Engl J Med. 2003; 348(24):2431-42. DOI: 10.1056/NEJMra023246. View

Im S, Lu Y, Bardia A, Harbeck N, Colleoni M, Franke F . Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019; 381(4):307-316. DOI: 10.1056/NEJMoa1903765. View

Nishimura R, Osako T, Okumura Y, Tashima R, Toyozumi Y, Arima N . Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. World J Surg Oncol. 2011; 9:131. PMC: 3214885. DOI: 10.1186/1477-7819-9-131. View

Milani A, Geuna E, Mittica G, Valabrega G . Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. World J Clin Oncol. 2014; 5(5):990-1001. PMC: 4259959. DOI: 10.5306/wjco.v5.i5.990. View

Baselga J, Im S, Iwata H, Cortes J, De Laurentiis M, Jiang Z . Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(7):904-916. PMC: 5549667. DOI: 10.1016/S1470-2045(17)30376-5. View

Finn R, Martin M, Rugo H, Jones S, Im S, Gelmon K . Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016; 375(20):1925-1936. DOI: 10.1056/NEJMoa1607303. View

Tripathy D, Bardia A, Sellers W . Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clin Cancer Res. 2017; 23(13):3251-3262. PMC: 5727901. DOI: 10.1158/1078-0432.CCR-16-3157. View

Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios C . 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017; 28(1):16-33. PMC: 5378224. DOI: 10.1093/annonc/mdw544. View

10.

Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, OReilly T, Evans D . Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res. 2005; 11(14):5319-28. DOI: 10.1158/1078-0432.CCR-04-2402. View

11.

Ali S, Coombes R . Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2003; 2(2):101-12. DOI: 10.1038/nrc721. View

12.

Robertson J, Lindemann J, Llombart-Cussac A, Rolski J, Feltl D, Dewar J . Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study. Breast Cancer Res Treat. 2012; 136(2):503-11. DOI: 10.1007/s10549-012-2192-4. View

13.

Robertson J, Bondarenko I, Trishkina E, Dvorkin M, Panasci L, Manikhas A . Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016; 388(10063):2997-3005. DOI: 10.1016/S0140-6736(16)32389-3. View

14.

Johnston S, Basik M, Hegg R, Lausoontornsiri W, Grzeda L, Clemons M . Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer. Breast Cancer Res Treat. 2016; 160(1):91-99. DOI: 10.1007/s10549-016-3979-5. View

15.

Wolff A, Lazar A, Bondarenko I, Garin A, Brincat S, Chow L . Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2012; 31(2):195-202. PMC: 3532391. DOI: 10.1200/JCO.2011.38.3331. View

16.

Schwartzberg L, Schwarzberg L, Franco S, Florance A, ORourke L, Maltzman J . Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010; 15(2):122-9. PMC: 3227947. DOI: 10.1634/theoncologist.2009-0240. View

17.

Muro K, Chung H, Shankaran V, Geva R, Catenacci D, Gupta S . Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016; 17(6):717-726. DOI: 10.1016/S1470-2045(16)00175-3. View

18.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

19.

Osborne C, Wakeling A, Nicholson R . Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004; 90 Suppl 1:S2-6. PMC: 2750773. DOI: 10.1038/sj.bjc.6601629. View

20.

STEPHEN R, Shaw L, Larsen C, Corcoran D, Darbre P . Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem. 2001; 276(43):40080-6. DOI: 10.1074/jbc.M105892200. View